The present study was conducted to obtain detailed information on the morphological changes in the human kidney as related to cisplatin therapy. The kidneys of ten autopsy cases showing impaired renal function following cisplatin therapy with hydration were examined histologically. Sporadic lesions of degeneration, necrosis, and regenerative changes were observed in the pars convoluta and pars recta of the proximal tubule, distal tubule, and collecting duct. Enlarged and pleomorphic nuclei in regenerated epithelial cells and hyperplasia of the collecting duct lining cells were considered to be specific histological findings in renal injury related to cisplatin therapy. Electron microscopic examination of a case receiving a large dose of cisplatin without signs of renal insufficiency showed an increased number of cytosomes containing electron dense granules in all tubular portions and conspicuous nuclear indentation in the thin limb of the loop of Henle and collecting duct. The platinum concentration in autopsy organs and biopsy cases was analyzed, but no correlation could be found between the concentration level of platinum in the kidney and impairment of renal function.
References
1.
1. Belt RT, Patton TF, Himmelstein KJ, Taylor S, Repta A, and Sternson LA (1980). Pharmacokinetics of cisplatin in humans. Proc. Am. Assoc. Cancer Res. (Cancer Res. Suppl.) 21: 193.
2.
2. Berry JP, Brille P, LeRoy AF, Gouveia Y, Riband P, Galle P, and Mathe G (1982). Experimental ultrastructural and X-ray microanalysis study of cisplatin in the rat: Intracellular localization of platinum.Cancer Treat. Rep.66: 1529–1533.
3.
3. Choie DD, Longnecker DS, and Del Campo AA (1981). Acute and chronic cisplatin nephropathy in rats.Lab. Invest.44: 397–402.
4.
4. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger J, Flamenbaum W, and Trump BF (1982). Cis-diamminedichlor-platinum-induced acute renal failure in the rat.Kidney Int.21: 54–64.
5.
5. Comis RL (1981). Cisplatin nephrotoxicity: The effect of dose, schedule, and hydration scheme. In: Cisplatin, AW Prestako, ST Crooke, and ST Carter, (eds). Academic Press, New York, London, pp. 485–494.
6.
6. DeConti RC, Tofness BR, Lange RC, and Creasay WA (1973). Clinical and pharmacological studies with cis-diamminedichloro-platinum (II).Cancer Res.33: 1310–1315.
7.
7. Daley-Yates PT and McBrien DCH (1984). Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumor activity of cisplatin.Biochem. Pharmacol.33: 3063–3070.
8.
8. Dentino M, Luft FC, Yum MN, Williams SD, and Einhorn LH (1978). Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man.Cancer41: 1274–1281.
9.
9. Dobyan DC, Levi J, Jacobs C, Kosek J, and Weiner MW (1980). Mechanism of cis-platinum nephrotoxicity: II. Morphologic observation.J. Pharmacol. Exp. Ther.213: 551–556.
10.
10. Ghadially FN, Lock CJL, Yang-Steppuhn S-E, and Lalonde J-MA (1981). Platinosomes produced in cultured cells by platinum coordination complexes.J. Submicrosc. Cytol.13: 223–230.
11.
11. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, and Sternberg SS (1977). The renal pathology in clinical trials of cis-platinum (II) diamminedichloride.Cancer39: 1362–1371.
12.
12. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, and Sternberg SS (1978). Acute renal failure after cis-dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies.Cancer Treat. Rep.62: 693–698.
13.
13. Hardaker WT Jr, Stone RA, and McCoy R (1974). Platinum nephrotoxicity.Cancer34: 1030–1032.
14.
14. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, and King JJ (1975). Clinical studies of platinum coordination compound in the treatment of various malignant diseases. Cancer Chemother. Rep. Part 159: 647–659.
15.
15. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, and Sterson LA (1981). Clinical kinetics of intact cisplatin and some related species.Clin. Pharmacol. Ther.29: 658–664.
16.
16. Holdener EE, Park CH, Belt RJ, Stephens RI, and Hoogstraten B (1978). Effect of mannitol and human plasma on cytotoxicity of cis-diamminedichloroplatinum. Clin. Res.26: 436A.
17.
17. Holthöfer H (1983). Lectin binding sites in kidney. A comparative study of 14 animal species.J. Histochem. Cytochem.31: 531–537.
18.
18. Jacobs C, Kalman SM, Tretton M, and Weiner MW (1980). Renal handling of cis-diamminedichloroplatinum (II).Cancer Treat. Rep.64: 1223–1226.
19.
19. Jacobs C, Coleman CN, Rich L, Hirst K, and Weiner MW (1984). Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.Cancer Res.44: 3632–3635.
20.
20. Lelieveld P, Van Der Vijgh WJF, Veldhuizen RW, Van Velzen D, Van Puten LM, Stassi G, and Danguy A (1984). Preclinical studies on toxicity, antitumor activity and pharmacokinetics of cisplatin and three recently developed derivatives.Eur. J. Cancer Clin. Oncol.20: 1087–1104.
21.
21. Leroy AF, Lutz RJ, Dedrick RL, Litterst CL, and Guarino AM (1979). Pharmacokinetic study of cis-dichlorodiammineplatinum (II) (CDDP) in the beagle dog: Thermodynamic and kinetic behavior of CDDP in biologic milieu.Cancer Treat. Rep.63: 59–71.
22.
22. Litterst CL, Gram TE, Dedrick RL, Leroy AF, and Guarino AM (1976). Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum (II) (NSC 119875) to dogs.Cancer Res.36: 2304–2344.
23.
23. Mizumura Y, Matsumoto M, Takata M, Iida H, and Sugimoto T (1983). [A case of cisplatin induced acute renal failure.] (In Japanese.)J. Jap. Soc. Intern. Med.72: 1426–1431.
24.
24. Ross DA and Gale GR (1979). Production of the renal toxicity of cis-dichlorodiammineplatinum (II) by probenecid.Cancer Treat. Rep.63: 781–787.
25.
25. Piel IJ and Rerlia CP (1975). Phase II study of cis-dichlorodiammineplatinum (II) (NS 119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancy.Cancer Chemother. Rep.59: 995–999.
26.
26. Salem PA, Jabboury W, and Khalil MF (1982). Severe nephrotoxicity: A probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy.Oncology39: 31–32.
27.
27. Weiss RB and Poster DS (1982). The renal toxicity of cancer chemotherapeutic agents.Cancer Treat. Rep.9: 37–56.
28.
28. Yogota A, Watson RC, Gonzalez-Vitale JC, Grabstald H, and Whitemore WF (1976). Cis-dichlorodiammineplatinum (II) in advanced bladder cancer.Cancer Treat. Rep.60: 917–923.
29.
29. Zollinger HU (1966). Die Nephrosen. In: Spezielle Pathologische Anatomie, W Dörre (ed). Band III, Springer-Verlag, Berlin, p. 179–318.
